Processa Pharmaceuticals, Inc. SEC filings PCSA
Processa Pharmaceuticals, Inc. has 705 filings in SEC EDGAR's recent list, going back to Oct 28, 2011. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Nov 5, 2026 | — |
| DEFA14A | Additional proxy material | Nov 5, 2026 | — |
| DEF 14A | Proxy statement | Oct 22, 2026 | Nov 30, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 9, 2026 | Oct 9, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 9, 2026 | Oct 9, 2026 |
| DEF 14A | Proxy statement | Jun 18, 2026 | Jun 18, 2026 |
| DEFA14A | Additional proxy material | Aug 25, 2025 | — |
| DEF 14A | Proxy statement | Aug 13, 2025 | Aug 13, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2025 | Jul 31, 2025 |
| DEF 14A | Proxy statement | May 12, 2025 | May 12, 2025 |
| DEFA14A | Additional proxy material | May 12, 2025 | — |
| PRE 14A | Preliminary proxy statement | May 1, 2025 | May 1, 2025 |
| DEFA14A | Additional proxy material | Apr 29, 2024 | — |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEFA14A | Additional proxy material | Oct 5, 2023 | — |
| DEF 14A | Proxy statement | Oct 5, 2023 | Oct 5, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 25, 2023 | Sep 25, 2023 |
| DEFA14A | Additional proxy material | May 1, 2023 | — |
| DEF 14A | Proxy statement | May 1, 2023 | May 1, 2023 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2023 | Apr 14, 2023 |
| DEFA14A | Additional proxy material | May 31, 2022 | — |
| DEF 14A | Proxy statement | May 31, 2022 | May 31, 2022 |
| DEFA14A | Additional proxy material | Sep 20, 2021 | — |
| DEF 14A | Proxy statement | Sep 20, 2021 | Sep 20, 2021 |
| PRE 14A | Preliminary proxy statement | Sep 1, 2021 | Sep 1, 2021 |
| DEFA14A | Additional proxy material | Apr 26, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Apr 22, 2021 |
| DEF 14C | Information statement | May 27, 2020 | May 27, 2020 |
| PRE 14C | Filing | May 15, 2020 | May 15, 2020 |
| DEF 14C | Information statement | Nov 25, 2019 | Nov 25, 2019 |
| PRE 14C | Filing | Nov 12, 2019 | Nov 12, 2019 |
| DEF 14C | Information statement | Jul 18, 2019 | Jul 18, 2019 |
| PRE 14C | Filing | Jul 2, 2019 | Jul 2, 2019 |
| DEF 14A | Proxy statement | Apr 26, 2019 | Apr 26, 2019 |
Showing 34 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vero Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1533743
- Former names
- Heatwurx, Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.